Ascendis Pharma A/S’s (ASND) “Outperform” Rating Reaffirmed at Royal Bank Of Canada

Ascendis Pharma A/S (NASDAQ:ASND)‘s stock had its “outperform” rating reaffirmed by stock analysts at Royal Bank Of Canada in a report issued on Friday, Benzinga reports. They currently have a $290.00 target price on the biotechnology company’s stock. Royal Bank Of Canada‘s price objective would indicate a potential upside of 6.88% from the stock’s previous close.

Other equities research analysts also recently issued research reports about the stock. Citigroup reduced their price target on shares of Ascendis Pharma A/S from $360.00 to $330.00 and set a “buy” rating for the company in a research report on Monday, October 26th. Cantor Fitzgerald boosted their target price on shares of Ascendis Pharma A/S from $300.00 to $315.00 and gave the company an “overweight” rating in a research note on Friday. TD Cowen boosted their target price on shares of Ascendis Pharma A/S from $341.00 to $352.00 and gave the company a “buy” rating in a research note on Friday. Morgan Stanley reduced their target price on Ascendis Pharma A/S from $275.00 to $273.00 and set an “overweight” rating for the company in a report on Tuesday, September 1st. Finally, Raymond James Financial cut Ascendis Pharma A/S from a “strong-buy” rating to an “outperform” rating and set a $287.00 target price for the company. in a research report on Tuesday, September 15th. Nineteen analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $307.10.

Ascendis Pharma A/S Trading Up 1.6%

Shares of ASND traded up $4.25 during midday trading on Friday, hitting $271.32. The stock had a trading volume of 28,649 shares, compared to its average volume of 699,983. Ascendis Pharma A/S has a fifty-two week low of $188.08 and a fifty-two week high of $282.15. The business has a 50-day simple moving average of $242.58 and a two-hundred day simple moving average of $239.65. The firm has a market cap of $16.93 billion, a P/E ratio of 20.94 and a beta of 0.40. The company has a current ratio of 2.99, a quick ratio of 2.32 and a debt-to-equity ratio of 0.27.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Friday, August 14th. The biotechnology company reported $1.03 earnings per share for the quarter, missing the consensus estimate of $1.71 by ($0.68). Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%. The firm had revenue of $387.22 million during the quarter, compared to analysts’ expectations of $376.75 million. As a group, equities analysts forecast that Ascendis Pharma A/S will post 3.43 EPS for the current year.

Insiders Place Their Bets

In other news, SVP Mads Bodenhoff sold 3,000 shares of the company’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $270.19, for a total value of $810,570.00. Following the transaction, the senior vice president owned 3,000 shares in the company, valued at $810,570. This represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 40.00% of the stock is currently owned by company insiders.

Institutional Trading of Ascendis Pharma A/S

Several institutional investors have recently made changes to their positions in ASND. Perceptive Advisors LLC grew its position in Ascendis Pharma A/S by 41.6% during the first quarter. Perceptive Advisors LLC now owns 1,531,421 shares of the biotechnology company’s stock valued at $350,282,000 after purchasing an additional 450,000 shares in the last quarter. Sei Investments Co. increased its stake in Ascendis Pharma A/S by 24.8% in the 1st quarter. Sei Investments Co. now owns 351,146 shares of the biotechnology company’s stock valued at $80,318,000 after buying an additional 69,673 shares during the period. Frazier Life Sciences Management L.P. lifted its position in Ascendis Pharma A/S by 68.9% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 225,155 shares of the biotechnology company’s stock worth $60,053,000 after buying an additional 91,822 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its position in Ascendis Pharma A/S by 27.0% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 227,013 shares of the biotechnology company’s stock worth $51,602,000 after buying an additional 48,275 shares in the last quarter. Finally, Orbimed Advisors LLC lifted its position in Ascendis Pharma A/S by 5.8% in the 1st quarter. Orbimed Advisors LLC now owns 181,977 shares of the biotechnology company’s stock worth $41,624,000 after buying an additional 10,000 shares in the last quarter.

Latest Ascendis Pharma A/S News

Here’s some of the latest news about ASND:

• Positive Sentiment: Analysts mostly raised their targets. TD Cowen lifted its target to $352 and Cantor Fitzgerald to $315, both retaining bullish ratings. Canaccord also raised its target, to $274, while keeping a hold rating. These revisions signal improved expectations, though price targets are not guarantees. TD Cowen ratings
• Positive Sentiment: Regulatory progress could support future growth. European regulators recommended marketing authorization for TransCon CNP; Ascendis expects a European Commission decision in Q4 2026 and plans a first launch in Germany in Q1 2027. Q3 results and pipeline update
• Negative Sentiment: One target was lowered. HC Wainwright cut its target from $344 to $335, though it maintained a buy rating. HC Wainwright ratings

About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines. Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism.